Amgen Inc. said its investigational biosimilar treatment for moderate-to-severe rheumatoid arthritis demonstrated clinical equivalence in safety and effectiveness withAbbVie ’s Humira after 24 weeks in a phase III study. The investigational treatment, called ABP 501, is being developed as a biosimilar to adalimumab, which is marketed under the brand name Humira.

Click Here to read more